Background {#Sec1}
==========

Brain metastases (BM) are the most common tumors of the central nervous system (CNS) and associated with a decline of survival time \[[@CR1]\]. Small cell lung cancer patients have a particularly high propensity to develop BM as 10--20% of patients present with BM already at diagnosis of the primary tumor and up to 50% experience symptomatic BM during their course of disease \[[@CR2], [@CR3]\]. Treatment possibilities for symptomatic BM are limited and mainly based on local approaches including neurosurgical resection, stereotactic radiosurgery (SRS) and whole-brain radiation therapy (WBRT) \[[@CR4]\]. Chemotherapy has only limited value in BM treatment of SCLC patients, although some small studies support a clinically meaningful intracranial activity \[[@CR5], [@CR6]\]. Prophylactic cranial irradiation (PCI), has been investigated extensively to prevent the occurrence of symptomatic BM, however is discussed controversially due to the lack of survival improvement in the light of severe, quality-of-life impairing side effects \[[@CR7]\].

Precise survival prognosis estimation is an essential foundation for therapeutic decisions in patients suffering from SCLC BM. In this highly palliative setting with survival times ranging from few days to months, therapeutic approaches have to carefully consider a personalized benefit-risk ratio \[[@CR8]\]. Standard prognostic scores such as the graded prognostic assessment (GPA), recursive partitioning analysis (RPA) and the more validated Diagnostic-Specific Graded Prognostic Assessments (DS-GPA) are based on clinical characteristics like patient age, Karnofsky Performance Scale (KPS), status of the extracranial disease, number of BM and primary tumor type \[[@CR8]--[@CR10]\]. The recently introduced LabBM score includes standard laboratory values to provide a more accurate survival estimation \[[@CR11]\]. In the present study we aimed to investigate clinical prognostic factors, established prognostic scores as well as the newly introduced LabBM score in a large, real life cohort of SCLC BM patients treated at the Medical University of Vienna over a time period of more than 20 years.

Methods {#Sec2}
=======

Patients {#Sec3}
--------

Patient treated for SCLC BM at the Medical University of Vienna between 1990 and 2018 were identified from the Vienna Brain Metastasis Registry \[[@CR12]\]. Clinical characteristics including course of disease, applied therapies and survival times were retrospectively evaluated by chart review. All patients were treated according to best clinical practice based on the discussion in a multidisciplinary tumor board.

SCLC were divided into limited and extensive disease according to published clinical practice guidelines of the European Society of Medical Oncology (ESMO) \[[@CR13]\]. Prognostic scores including RPA, GPA and DS-GPA were calculated based on clinical characteristics as published previously \[[@CR7], [@CR9], [@CR11]\]. In short, age, number of BM, status of the extracranial disease and KPS were evaluated and combined in the DS-GPA class for lung cancer \[[@CR8]\]. The LabBM score was calculated as previously published based on serum heamoglobin concentration, platelet counts, serum albumin concentration, serum lactate dehydrogenase concentration and serum c-reactive protein concentration \[[@CR11]\].

Synchronous diagnosis was defined as diagnosis of primary tumor and BM/extracranial metastasis within 30 days. Neurological symptoms were defined according to the written reports as either neurological deficits (any of the following: motor disorders, hypoesthesia, cranial nerve disfunction, cognitive impairment, vertigo and organic brain disorder), or signs of increased intracranial pressure (any of the following: headache, nausea, emesis) or epileptic seizures (focal or generalized seizures). If any of these neurological symptoms was presented the patient was categorized as symptomatic. If none of the listed neurological symptoms was present the patient was categorized as a- to oligosymptomatic. High symptomatic burden was defined as the presence of two or more neurological symptoms at BM diagnosis.

End of life disease status was evaluated based on the last available complete re-staging including extracranial as well as intracranial disease status within the last 60 days of life. Death due to intracranial progression was indicated in the absence of extracranial progression but clear increase in intracranial tumor burden. In contrast, death due to extracranial progression was defined in absence of intracranial progression, but increase in extracranial tumor burden in the last re-staging. Patient data were collected in a password secured database and handled anonymously. The study was approved by the ethics committee of the Medical University of Vienna (vote 078/2004).

Statistical analysis {#Sec4}
--------------------

Overall survival time (OS) from primary tumor diagnosis was defined as time from initial histological diagnosis of the primary tumor to death or last follow-up. OS from BM diagnosis was defined as the time from initial radiological diagnosis of BM to death or last follow-up. Brain metastatic free survival was defined as time from diagnosis of primary tumor to radiological diagnosis of BM. Patients with synchronous diagnosis (within 30 days) of primary tumor and BM were excluded from analysis investigating the brain metastatic free survival period.

Chi square test was applied to analyze differences between two dichotomous variables. Kaplan Meier product limit methods were used for survival estimations and the log rank test was applied to analyze survival differences between groups. Parameters with statistically significant association with survival prognosis in the univariate analysis were included in multivariate analysis with the established prognostic scores using the Cox proportional hazard model. A two-sided p-value of \< 0.05 was considered to indicate statistical significance. Due to the exploratory and hypothesis-generating design of the present study, no adjustment for multiple testing was applied \[[@CR14]\].

Results {#Sec5}
=======

Patients characteristics {#Sec6}
------------------------

489 patients (male 304/489 (62.2%); female 185/489 (37.8%)) with newly diagnosed SCLC BM were available for further analysis. Median age at diagnosis of SCLC was 61 years (range 38--88 years). Table [1](#Tab1){ref-type="table"} and Supplementary Table 1 lists further patient's and clinical characteristics.Table 1Clinical and patient's characteristicsCharacteristics at BM diagnosisEntire population (n = 489)n%Gender Male30462.2 Female18537.8Median age at BM diagnosis61(38--89)Median time from diagnosis of SCLC to BM development (range)5 (0--102)Status of SCLC at BM diagnosis Synchronous diagnosis of extracranial metastases and BM19840.5% Stable disease11222.9% Progressive disease10220.9% Complete response30.6% Partial response6112.5% No evidence of extracranial disease after surgical resection of SCLC132.7%Synchronous diagnosis of extracranial metastases and BM Yes15631.9% No33368.1%Median Karnofsky Performance Score80 (10--100)Neurological symptoms Present34069.5% Absent (diagnosis during screening)14930.5%  Neurological deficits   Present29760.7%   Absent19239.3%  Signs of increased intracranial pressure   Present12224.9%   Absent36775.1%  Seizures   Present6613.5%   Absent42386.5% Number of neurological signs at BM diagnosis  120141.1%  ≥ 213928.4%Characteristics after BM diagnosis First line treatment of BM  SRS21243.4%  Chemotherapy81.6%  Surgery7515.3%  WBRT17636.0%  Best supportive Care183.7% Systemic progression after first line BM treatment  Yes24850.7%  No24149.3% Median time from first BM treatment to systemic progression in months (range)3 (0--91) Intracranial progression after first line BM treatment  Yes20441.7%  No28558.3% Median time from first BM treatment to intracranial progression in months (range)7 (0--77) Status at last follow-up  Deceased44490.8%  Alive459.2% Median overall survival from diagnosis of BM (range)6 (0--264)*BM* brain metastasis, *SCLC* small cell lung cancer, *PCI* Prophylactic cranial irradiation, *SRS* Stereotactic radiosurgery, *WBRT* Whole brain radiation therapy

Clinical characteristics associated with time to SCLC BM development {#Sec7}
--------------------------------------------------------------------

198/489 (40.5%) patients presented with synchronous diagnosis of BM and primary tumor and in consequence did not receive any tumor related treatment before the diagnosis of BM. Median BM free survival of the 291/489 (59.5%) patients with subsequent BM diagnosis was 10 months (range 3--102).

158/489 (32.3%) patients diagnosed with limited SCLC showed a median brain metastatic free survival of 11 months (range 3--102) while 331/489 (67.7%) patients with extensive SCLC a median brain metastatic free survival of 9 months (range 2--42; p \< 0.001; log-rank test; Fig. [1](#Fig1){ref-type="fig"}a).Fig. 1Clinical characteristics during the course of SCLC disease including (**a**) brain metastatic free survival in extended compared to limited disease SCLC according disease status at SCLC diagnosis (**b**) patient's characteristics at BM diagnosis (**c**) first line treatment at diagnosis of BM (**d**) end of life disease status (**e**) overall survival according to synchronous compared to subsequent diagnosis of BM

Clinical characteristics at SCLC BM diagnosis {#Sec8}
---------------------------------------------

Median age at BM diagnosis was 61 years (range 38--89 years). 149/489 (30.5%) patients were diagnosed with BM during routine screening or staging procedures in absence of BM specific symptoms. In the time period from 1990--2000, less patients were diagnosed in a- to oligosymptomatic stage due to screening (43/178; 24.2%) compared to patients diagnosed after 2000 (106/311; 34.1%; p = 0.022; chi-square test). Overall, 340/489 (69.5%) patients presented with at least one neurological symptom at BM diagnosis. In more detail, 297/489 (60.7%) patients suffered from neurological deficits, 122/489 (24.9%) patients from signs of increased intracranial pressure and 66/489 (13.5%) patients presented with seizures. 139/489 (28.4%) patients presented with highly symptomatic BM disease at diagnosis as 2 or more neurological symptoms were presented (Fig. [1](#Fig1){ref-type="fig"}b; Table [1](#Tab1){ref-type="table"}).

Of 198/489 (40.5%) patients with synchronous diagnosis of SCLC and BM, 59/198 (29.8%) presented with a- to oligosymptomatic intracranial disease, while 139/198 (70.2%) patients presented with neurological symptoms (p = 0.790; chi-square test). Of 291/489 (59.5%) patients with subsequent BM diagnosis, 30.9% (90/291) were diagnosed with a- to oligosymptomatic intracranial disease, while 69.1% (201/291) of the patients suffered from neurological symptoms. (p = 0.13; chi-square test; Fig. [1](#Fig1){ref-type="fig"}c).

Table [1](#Tab1){ref-type="table"} and Supplementary Table 1 lists further patient's and clinical characteristics at BM diagnosis.

Clinical course after diagnosis of SCLC BM {#Sec9}
------------------------------------------

212/489 (43.4%) patients were treated with SRS as the first line treatment. Of these, 62.3% (132/212) presented with neurological symptoms at BM and in 50% (106/212) SRS was performed to singular BM, in 37.3% (79/212) to 2--3 BM and in 12.7% (27/212) to ≥ 4 BM (Supplementary Table 1). In 42/212 (19.8%) patients treated with SRS, additional adjuvant WBRT was applied after SRS (Supplementary Table 1).

176/489 (36.0%) patients were treated with WBRT as the first line treatment approach. 58% (102/176) of these patients were diagnosed with ≥ 4 BM and 123/176 (69.9%) WBRT treated patients presented in a symptomatic status at BM diagnosis. (Supplementary Table 1).

Surgical resection as initial therapy of BM was performed in 75/489 (15.3%) patients (Fig. [1](#Fig1){ref-type="fig"}c; Table [1](#Tab1){ref-type="table"}). Of these, 92.0% (69/75) suffered from neurological symptoms at BM diagnosis and 65.3% (49/75) were diagnosed with singular BM.

248/489 (50.7%) patients experienced systemic progression after first line BM treatment. Median time to extracranial progression was 3 months (range 0--91 months). 204/489 (41.7%) patients presented with intracranial progression with a median time to intracranial progression of 7 months (range 0--77 months). No difference in the time to intracranial progression (p \> 0.05; log-rank test) or the development of intracranial progression (p \> 0.05; chi-square test) according to applied first line BM treatment approach was evident.

The cause of death based on a complete re-staging within 60 days before death could be evaluated in 339/444 (76.04%) patients (Fig. [1](#Fig1){ref-type="fig"}d; Table [1](#Tab1){ref-type="table"}). In 19/339 (5.6%) cases isolated intracranial progression in the absence of extracranial progression was the leading cause of death. 133/339 (39.2%) SCLC BM patients presented with progressive systemic disease in the absence of intracranial progression. In 176/339 (52.0%) combined intra- and extracranial progression was observed in the last re-staging examination before death. 11/339 (3.2%) patients died due to non-cancer related cause.

Survival time according to clinical characteristics at SCLC BM diagnosis {#Sec10}
------------------------------------------------------------------------

Median overall survival from BM diagnosis was 6 months (range 0--264) in the entire cohort. Median survival from SCLC diagnosis was 9 months in patients with synchronous BM diagnosis and 17 months in patients with subsequent BM diagnosis (p \< 0.001; log-rank test; Fig. [1](#Fig1){ref-type="fig"}e; Table [2](#Tab2){ref-type="table"}). However, median OS from diagnosis of BM was longer in patients with synchronous diagnosis of primary tumor and BM (9 months) compared to patients with subsequent BM diagnosis after primary SCLC diagnosis (5 months; p = 0.008; log-rank test; Fig. [1](#Fig1){ref-type="fig"}e; Table [2](#Tab2){ref-type="table"}).Table 2Clinical characteristics associated with OSCharacteristicsEntire population (n = 489)OS (median) in monthsp-valueYear of diagnosis \> 200070.056 ≤ 20006Synchronous diagnosis of SCLC and BM0.008 Yes9 No5Neurological symptoms0.022 Yes5 No7Neurological deficits0.001 Yes5 No8Signs of increased intracranial pressure0.692 Yes6 No6Seizures0.828 Yes5 No7Symptomatic burden0.373 High5 Low6First line treatment approach \< 0.001 WBRT5 SRS7 Neurosurgical resection11*BM* brain metastasis, *OS* overall survival, *SCLC* small cell lung cancer, *SRS* Stereotactic radiosurgery, *WBRT* Whole brain radiation therapy

Single parameters included in the RPA, GPA or DS-GPA including age, KPS, status of the extracranial disease and number of BM were significantly associated with survival prognosis from diagnosis of BM (Fig. [2](#Fig2){ref-type="fig"}a--d; Supplementary Table 2).Fig. 2Overall survival according to (**a**) age at BM diagnosis (**b**) KPS at BM diagnosis (**c**) presence of extracranial disease at BM diagnosis (**d**) number of BM at diagnosis (**e**) year of BM diagnosis (**f**) first-line BM treatment approaches

Presence of neurological symptoms was associated with impaired OS prognosis as symptomatic patients presented with a median OS of 5 months compared to 9 months in a- to oligosymptomatic patients (p = 0.030; log-rank test; Fig. [3](#Fig3){ref-type="fig"}a; Table [2](#Tab2){ref-type="table"}). In more detail, particular presence of neurological deficits was associated with impaired OS prognosis, as patients with neurological deficits presented with a median OS of 5 months compared to 8 months in patients without neurological deficits (p = 0.001; log-rank test; Fig. [3](#Fig3){ref-type="fig"}b; Table [2](#Tab2){ref-type="table"}). In line, signs of increased cranial pressure (6 vs. 5 months), epileptic seizures (7 vs. 5 months) and high symptomatic burden (6 vs. 5 months) were numerical associated with impaired OS prognosis, although not reaching statically significance (p \> 0.05; log-rank test; Supplementary Fig. 1a--c; Supplementary Table 2; Table [2](#Tab2){ref-type="table"}).Fig. 3Overall survival according to (**a)** presence of neurological symptoms at BM diagnosis (**b**) presence of neurological deficits at BM diagnosis (**c**) RPA classes (**d**) GPA-classes (**e**) DS-GPA-classes (**f**) LabBM score groups

Time of diagnosis was not associated with a statically significant impact on OS prognosis as patients diagnosed before 2000 presented with a median overall survival of 6 months compared to 7 months in patients diagnosed and treated after 2000 (p = 0.056; log-rank test; Fig. [2](#Fig2){ref-type="fig"}e; Table [2](#Tab2){ref-type="table"}). See Table [2](#Tab2){ref-type="table"} on more details of clinical characteristics impacting OS prognosis.

Survival differed between first line BM treatment approaches (p \< 0.001; log-rank test; Fig. [2](#Fig2){ref-type="fig"}f; Table [2](#Tab2){ref-type="table"}) as patients treated with neurosurgical resection showed a median OS from BM diagnosis of 11 months compared to patients who received SRS (7 months) or WBRT (5 months).

Validation of established prognostic scores in the Vienna SCLC BM real-life cohort {#Sec11}
----------------------------------------------------------------------------------

The prognostic scores RPA (p \< 0.001; log-rank test; Fig. [3](#Fig3){ref-type="fig"}c; Table [3](#Tab3){ref-type="table"}), GPA (p \< 0.001; log-rank test; Fig. [3](#Fig3){ref-type="fig"}d; Table [3](#Tab3){ref-type="table"}) and DS-GPA (p \< 0.001; log-rank test; Fig. [3](#Fig3){ref-type="fig"}e; Table [3](#Tab3){ref-type="table"}) could be validated in the present real-life cohort.Table 3Survival analysis according to prognostic scoresPrognostic scoresnEntire population (n = 489)%OS (median) in monthsp-valueHR95% CIRPA \< 0.0011.661.441.91 Class I11523.512 Class II26854.87 Class III10621.73DS-GPA \< 0.0011.601.431.80 Class I234.713 Class II14629.910 Class III18838.46 Class IV13227.03GPA \< 0.0011.651.441.89 Class I234.713 Class II541111 Class III27856.97 Class IV134273Lab-BM \< 0.0011.691.372.09 Low8249.711 Medium5432.74 High2917.63*CI* Confidence interval, *RPA* recursive partitioning analysis, *GPA* graded prognostic assessments, *DS-GPA* diagnostic-specific graded prognostic assessments, *HR* hazard ratio, *OS* overall survival

Complete data to calculate the LabBM score was available in 165/489 (33.7%) patients. 82/165 (49.7%) patients were categorized in low LabBM score group with a median overall survival of 11 months. The medium LabBM score group contained 54/165 (32.7%) patients showing a median survival rate of 4 months, followed by 3 months in the high LabBM score group including 29/165 (17.6%) patients (p \< 0.001; log-rank test; Fig. [3](#Fig3){ref-type="fig"}f; Table [3](#Tab3){ref-type="table"}).

Multivariate analysis of clinical factors impacting the survival prognosis of SCLC BM patients {#Sec12}
----------------------------------------------------------------------------------------------

In multivariate analysis including DS-GPA and neurological symptoms, only DS-GPA (HR 1.58; 95% CI 1.40--1.77; p \< 0.001; Cox regression model; Supplementary Table 3) remained statistically significant. In the multivariate Cox regression model of DS-GPA and neurological deficits, both, DS-GPA (HR 1.58; 95% CI 1.42--1.79; p \< 0.001; Cox regression model; Supplementary Table 3) and neurological deficits (HR 1.26; 95% CI 1.04--1.53; p = 0.021; Cox regression model; Supplementary Table 3) remained statistically significant. The multivariate analysis of DS-GPA (HR 1.59; 95% CI 1.41--1.78; p \< 0.001; Cox regression model; Supplementary Table 3) and synchronous diagnosis of BM (HR 0.84; 95% CI 0.69--1.02; Cox regression model; Supplementary Table 3) showed statistical significance only for DS-GPA. Furthermore, the multivariate analysis of DS-GPA and LabBM score showed statistically significant results for both variables (DS-GPA HR 1.67; 95% CI 1.36--2.05; p \< 0.001; Cox regression model; LabBM score HR 1.57; CI 1.27--1.94; p \< 0.001; Cox regression model; Supplementary Table 3).

Discussion {#Sec13}
==========

Precise prognostic evaluation is the basis for benefit-risk adapted treatment decisions in patients with newly diagnosed SCLC BM \[[@CR2], [@CR3]\]. Here, we were able to analyze clinical prognostic factors as well as the recently established LabBM score, combining several standard laboratory parameters in a unique and large cohort of patients treated for SCLC BM at a single center. We could validate the application of established prognostic scores like the RPA, the GPA and the DS-GPA, as well as the LabBM score and identify presence of neurological symptoms as a prognostic parameter in patients with SCLC BM. Given the currently still detrimental survival prognosis of SCLC BM patients, clinical trials taking in account the different prognostic groups are urgently needed to formulate new treatment approaches in this patient cohort of high clinical need.

In the present real-life cohort including over 480 patients with newly diagnosed SCLC BM, the previously established prognostic scores estimating the survival based on clinical variables like the KPS, presence of extracranial disease, number of BM and age at BM diagnosis could be validated \[[@CR8]--[@CR10]\]. Importantly, the RPA, the GPA as well as the DS-GPA score were established based on clinical study cohorts, including patients enrolled in clinical trials of the Radiation Therapy Oncology Group (RTOG). The prognostic score establishment was therefore potential biased by the enrolment of a selective patient cohort eligible for clinical trials as well as the inclusion time in the late 1980s to the early 2000. The OS in our cohort treated between 1990 and 2018 was slightly longer with a median OS of 6 months, compared to 4.9 months in the cohort used to established the DS-GPA including patients treated between 1993 and 2010 \[[@CR8]\]. Furthermore, we could validate the recently elaborated LabBM score, including standard laboratory variables as surrogate parameters for the patient's global health status. Our findings are well in line with another smaller recent cohort postulating serum LDH concentration as an independent predictor for prognosis after WBRT for BM from SCLC \[[@CR15]\]. Future clinical studies should therefore include the DS-GPA and potentially also the LabBM Score to identify prognostic homogenous cohorts.

Patients with neurological symptoms and in more detail with neurological deficits presented with impaired survival prognosis compared to patients with a- to oligosymptomatic disease. While the NANO scale, objectifying the symptomatic burden, is already a well-established part in the response assessment of primary brain tumors, so far the prognostic assessment in newly diagnosed BM patients did not include symptom evaluation \[[@CR16]\]. Although screening for BM is discussed controversially in published guidelines, several centers throughout Europe frequently screen for BM in non-small cell lung cancer at diagnosis, resulting in a higher detection rate of a- or oligosymptomatic patients \[[@CR17]\]. A further consequence of BM screening is the higher detection rate of synchronous BM at SCLC diagnosis. In the present cohort, patients with synchronous diagnosis of BM presented with a longer OS from BM diagnosis compared to patients with subsequent diagnosis. However, the OS from diagnosis of SCLC was longer in patients with subsequent BM diagnosis. Patients with synchronous diagnosis are in contrast to patients with subsequent diagnosis therapy naïve at BM diagnosis and can still receive the full repertoire including systemic therapies \[[@CR13]\]. Indeed, BM screening potentially results in the frequent diagnosis of BM in an oligosymptomatic stage, however so far no impact of screening and earlier diagnosis of BM on OS prognosis could be validated. BM directed trials as well as BM specific endpoints in several recent trials for novel targeted and immune modulating therapies included specifically patients with oligo- to asymptomatic brain metastatic disease and could show a high intracranial, clinically meaningful efficacy for systemic treatment approaches \[[@CR18]--[@CR22]\]. In consequence, the EANO guidelines for treatment of BM patients currently suggests that systemic treatment options should be evaluated in asymptomatic BM patients suitable for a targeted therapy with proven intracranial efficacy \[[@CR4]\]. Recently, a phase III trial of the immune checkpoint inhibitor atezolizumab in combination with chemotherapy in patients with extensive-disease SCLC, including a small number of BM patients, revealed a significantly longer overall survival and progression-free survival in the atezolizumab combination group compared to chemotherapy alone. No survival difference was observed in the particular subgroup of SCLC BM patients, however the small sample size and the missing power to answer this particular question need to be considered in the interpretation \[[@CR23]\]. Given the high intracranial efficacy of immune checkpoint inhibitors in other entities, future clinical trials should further focus on the application of systemic therapy options in patients with SCLC BM. Here, the observed survival difference of patients with symptomatic versus patients with oligo- to asymptomatic brain metastatic disease should be considered in the clinical trial planning.

Although we were able to investigate clinical parameters in a large real-life cohort, some limitations have to be considered in the interpretation of our results. The long inclusion period from 1999 to 2018 potentially biased the results as diagnostic procedures improved over this time period. However, treatment algorithms in the particular context of SCLC BM did not change significantly. Further, the retrospective design of the study has limitation, although---to our best knowledge---this analysis is one of the so far largest real-life SCLC BM cohorts specifically addressing prognostic parameters. So far most authors concentrated on prognostic evaluation of NSCLC BM patients and structured investigation of clinical prognostic parameters in SCLC BM patients was missing \[[@CR9], [@CR24]\]. Here, we could include 489 patients who underwent treatment for BM from SCLC at a single institution. Therefore, the present study gives the unique opportunity to gain a deeper insight into potential prognostic factors and the clinical course of brain metastatic SCLC disease over a time period of more than 20 years.

In conclusion, this study presents a detailed clinical characterization of a unique, large real-life cohort of SCLC BM patients. Our study highlights the heterogeneity of BM treatment in a unique real-life single center cohort of SCLC BM patients and may be useful to formulate new clinical studies. Prognostic scores including the DS-GPA as well as the LabBM score could be validated for the specific cohort of SCLC BM and should be applied in future clinical trials. Further, our data stresses the importance to evaluate symptomatic and a- to oligosymptomatic patients separately due to the differing survival prognosis.
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